Dow Inc.
DOW
$36.27
-3.90%
Dow Inc. is a global leader in the chemicals industry, producing a diversified portfolio of materials science products including polyethylene, ethylene oxide, and silicone rubber. The company operates as a major player in basic materials, serving a wide range of consumer and industrial end markets. The current investor narrative is dominated by the significant impact of Middle East geopolitical tensions on its supply chain and financial performance, as evidenced by recent quarterly results showing a revenue miss and widening losses. However, recent news of de-escalation in the Strait of Hormuz and the company's optimistic forward guidance alongside cost-saving initiatives are fueling a debate around its potential for a recovery and margin normalization.…
DOW
Dow Inc.
$36.27
Related headlines
Investment Opinion: Should I buy DOW Today?
Rating: Hold. The core thesis is that DOW is a high-risk, high-reward cyclical recovery play where the potential upside from geopolitical normalization is currently balanced by severe fundamental weakness, warranting a cautious stance pending clearer evidence of margin improvement.
The Hold rating is supported by conflicting data points: the compelling valuation discount (PS of 0.416), the strong technical recovery trend (+68.99% over 6 months), and analyst optimism (forward EPS $2.27) argue for a Buy. However, these are counterbalanced by alarming profitability metrics (gross margin of 5.79%, negative FCF), a leveraged balance sheet (D/E of 1.22), and the stock's proximity to its 52-week high after a major rally, limiting near-term upside.
The two biggest risks that could invalidate a more bullish view are 1) a failure of gross margins to recover above 8% in the next two quarters, and 2) a continuation of negative free cash flow forcing balance sheet action. This Hold would upgrade to a Buy if the PS ratio remains below 0.5 while quarterly FCF turns positive, or if the stock experiences a pullback to the low $30s offering a better entry point. It would downgrade to a Sell if revenue declines accelerate beyond -10% YoY or if net debt increases significantly. Relative to its own distressed history, the stock is fairly valued for the current level of risk, but it is undervalued relative to a normalized earnings scenario.
Sign up to view all
DOW 12-Month Price Forecast
The outlook for DOW is a binary bet on the speed of its operational recovery. The neutral stance reflects the high probability (50%) assigned to a slow, grinding base-case recovery where the stock treads water. The bull case has a credible 30% probability given the powerful removal of the geopolitical overhang, but it requires flawless execution on cost savings. The bear case, while lower probability, carries a severe downside risk to the $20 level. The stance would upgrade to bullish on confirmation of two consecutive quarters of margin expansion and positive free cash flow. It would turn bearish if the next quarterly report shows further margin compression or a guidance withdrawal.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dow Inc.'s 12-month outlook, with a consensus price target around $47.15 and implied upside of +30.0% versus the current price.
Average Target
$47.15
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$29 - $47
Analyst target range
The stock is covered by 10 analysts, indicating a solid level of institutional research coverage. The consensus sentiment appears mixed but leaning towards cautious optimism, as evidenced by recent rating actions including upgrades from Citigroup (to Buy) and RBC Capital (to Outperform) in March 2026, alongside reaffirmations of Neutral/Hold ratings from firms like Mizuho and UBS. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $2.27 for the upcoming period, suggesting an expectation of a significant earnings recovery from current losses. Without a specific consensus price target, the implied upside cannot be calculated, but the recent upgrades signal a belief among some analysts that the stock has oversold the near-term geopolitical risks and that cost-saving initiatives and a reopening of trade routes could drive a rebound. The target price range, derived from revenue estimates, shows a low of $45.48 billion and a high of $46.39 billion in estimated revenue, indicating a relatively tight band and moderate consensus on the top-line outlook. The wide dispersion in recent analyst actions—from upgrades to maintains—signals high uncertainty around the timing and magnitude of a recovery, with the key debate centered on the duration of supply chain impacts and the company's ability to restore margins.
Bulls vs Bears: DOW Investment Factors
The investment debate for DOW centers on a classic cyclical recovery thesis clashing with severe near-term fundamental deterioration. The bull case, currently supported by stronger technical and sentiment evidence, hinges on the stock's deep valuation discount and the powerful catalyst of geopolitical de-escalation unlocking a return to normalized operations and profitability. The bear case is grounded in the alarming collapse of margins and cash flow, which raises solvency concerns if the recovery is delayed. The single most important tension is the timing and magnitude of the margin recovery. If cost-saving initiatives and reopened trade routes allow gross margins to rebound toward historical levels (e.g., above 10%) within the next two quarters, the bull thesis will be validated. If margin pressure persists beyond 275 days as management warned, the bear case of prolonged cash burn and balance sheet stress will dominate.
Bullish
- Deep Cyclical Valuation Discount: The stock trades at a trailing Price-to-Sales ratio of 0.416, a severe discount from its 2.71 PS ratio a year ago. This valuation near historical lows prices in extreme pessimism, offering significant upside if fundamentals merely stabilize.
- Strong Technical Uptrend & Momentum: DOW has gained 68.99% over the past six months and 29.60% over the past year, significantly outperforming the S&P 500. Trading at 87% of its 52-week range ($20.40 to $42.74) indicates sustained bullish momentum and a recovery from its lows.
- Geopolitical De-escalation Catalyst: Recent news confirms the Strait of Hormuz has reopened, removing a major supply chain overhang that caused Q1 2026 revenue to miss and losses to widen. This key catalyst could rapidly normalize logistics and reduce cost pressures, supporting the company's optimistic Q2 guidance.
- Analyst Upgrades Signal Recovery Belief: Recent upgrades from Citigroup (to Buy) and RBC Capital (to Outperform) in March 2026 reflect a growing analyst view that the stock has oversold near-term risks. The average forward EPS estimate of $2.27 implies a strong expected earnings recovery from the current Q4 2025 loss of -$2.15 per share.
Bearish
- Severe Profitability & Cash Flow Collapse: Q4 2025 saw a net loss of -$1.54B, a gross margin collapse to 5.79% from 8.43% a year ago, and negative free cash flow of -$1.45B for the quarter. Trailing-twelve-month free cash flow is -$2.61B, indicating the company is burning cash to fund operations.
- Sharp Revenue Contraction & Deteriorating Trends: Revenue declined -9.08% YoY in Q4 2025 to $9.46B, following a sequential drop from $10.41B in Q4 2024. This indicates a deteriorating top-line environment, with the key Packaging & Specialty Plastics segment revenue of $4.74B reflecting the impact of supply chain disruptions.
- High Financial Leverage Amid Losses: A debt-to-equity ratio of 1.22 indicates a leveraged capital structure. Servicing this debt becomes challenging with a negative Return on Equity of -16.39% and significant operating losses, increasing refinancing risk if the downturn is prolonged.
- Vulnerability Near 52-Week High: Trading at $38.75 places the stock just 9.3% below its 52-week high of $42.74, following a sharp 68.99% six-month rally. This leaves it vulnerable to a technical pullback, especially given the recent -23.17% one-month decline shows high volatility and profit-taking.
DOW Technical Analysis
The stock is in a sustained uptrend, with a 1-year price change of +29.60% and a 6-month surge of +68.99%, significantly outperforming the broader market. As of the latest close at $38.75, the price is trading at approximately 87% of its 52-week range ($20.40 to $42.74), positioning it near the high end of its yearly band. This proximity to the 52-week high suggests strong bullish momentum but also raises concerns about potential overextension and vulnerability to a pullback. Recent momentum shows signs of consolidation and volatility, with a 1-month decline of -23.17% contrasting sharply with the robust 3-month gain of +19.27%. This divergence from the longer-term uptrend indicates a significant short-term correction, likely driven by the Q1 earnings miss and geopolitical news, testing the strength of the prevailing bullish trend. Key technical support is anchored at the 52-week low of $20.40, while immediate resistance sits at the yearly high of $42.74. A decisive breakout above $42.74 would signal a resumption of the primary uptrend, whereas a breakdown below the recent consolidation lows around $35.60 could indicate a deeper correction. The stock's beta of 0.454 indicates it is roughly 55% less volatile than the S&P 500 (SPY), which has gained 25.19% over the past year, suggesting DOW has exhibited defensive characteristics with lower market-correlated risk, though its recent sharp moves show idiosyncratic event-driven volatility.
Beta
0.45
0.45x market volatility
Max Drawdown
-33.3%
Largest decline past year
52-Week Range
$20-$43
Price range past year
Annual Return
+21.8%
Cumulative gain past year
| Period | DOW Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +4.6% |
| 3m | +15.5% | +8.3% |
| 6m | +63.4% | +12.5% |
| 1y | +21.8% | +25.0% |
| ytd | +49.4% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOW Fundamental Analysis
Dow's revenue trajectory is under significant pressure, with Q4 2025 revenue of $9.46 billion reflecting a year-over-year decline of -9.08%. This contraction follows a sequential decline from $10.41 billion in Q4 2024, indicating a deteriorating top-line environment, primarily driven by Middle East supply chain disruptions impacting its key segments. The Packaging & Specialty Plastics segment, the largest contributor at $4.74 billion in the latest quarter, is a critical focus, while Industrial Intermediates & Infrastructure ($2.69B) and Performance Materials & Coatings ($1.85B) round out the portfolio. Profitability has sharply reversed, with the company reporting a net loss of -$1.54 billion in Q4 2025, compared to a net loss of -$53 million in the year-ago quarter. The gross margin has collapsed to 5.79% in Q4 2025 from 8.43% in Q4 2024, highlighting severe margin compression. This unprofitable trend is a stark departure from the profitable quarters earlier in 2024, such as Q2 2024's net income of $439 million, signaling a rapid and severe downturn in the business cycle. The balance sheet shows a debt-to-equity ratio of 1.22, indicating a leveraged capital structure, though the current ratio of 1.97 suggests adequate short-term liquidity. More concerning is the free cash flow, which was negative -$1.45 billion for Q4 2025 and -$2.61 billion on a trailing-twelve-month basis, indicating the company is consuming cash to fund operations and capital expenditures. The negative Return on Equity of -16.39% further underscores the recent destruction of shareholder value and weak operational efficiency.
Quarterly Revenue
$9.5B
2025-12
Revenue YoY Growth
-0.09%
YoY Comparison
Gross Margin
+0.05%
Latest Quarter
Free Cash Flow
$-2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOW Overvalued?
Given the negative net income of -$1.54 billion for Q4 2025, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Dow's trailing PS ratio is 0.416, while its forward valuation is not explicitly provided in the data, but the low PS multiple reflects the market's discount for a company experiencing significant earnings distress. The stock trades at a substantial discount to its own historical valuation, as its PS ratio of 0.416 is far below the 2.71 level from Q4 2024, indicating the market has severely de-rated the stock due to its recent fundamental deterioration. Compared to industry averages, specific sector PS data is not provided in the dataset, but a sub-0.5x sales multiple is typically very low for a chemicals company, suggesting the market is pricing in a deep cyclical trough or sustained challenges. The current valuation near historical lows presents a potential value opportunity if the company can execute a turnaround, but it also reflects justified pessimism given the sharp decline in profitability and negative cash flow. The forward PE of 18.12, based on analyst estimates, implies the market expects a return to profitability, creating a wide gap between the negative trailing PE of -6.34 and the positive forward outlook.
PE
-6.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -133x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company is experiencing a cash burn crisis, with Q4 2025 free cash flow at -$1.45 billion and TTM FCF at -$2.61 billion. This is compounded by a gross margin collapse to 5.79% and a net loss of -$1.54 billion for the quarter. With a debt-to-equity ratio of 1.22, the leveraged balance sheet is under significant stress while profitability is negative, increasing refinancing risk. Revenue concentration is also a risk, as the largest segment (Packaging & Specialty Plastics, $4.74B) is directly exposed to the disrupted supply chains.
Market & Competitive Risks stem from its cyclical nature and valuation. While the PS ratio of 0.416 is deeply discounted, the forward PE of 18.12 implies the market expects a sharp V-shaped earnings recovery. Any delay in this recovery could lead to multiple compression. The stock's low beta of 0.454 offers some defensive appeal but does not shield it from industry-specific downturns. The recent 68.99% six-month surge has pushed the stock near its 52-week high, making it vulnerable to profit-taking and sector rotation away from recovery stories if macro conditions worsen.
Worst-Case Scenario involves a prolonged global chemical downturn exacerbated by a resurgence of Middle East tensions, preventing margin recovery. In this scenario, cash burn continues, forcing the company to draw down liquidity or raise expensive capital, leading to credit downgrades and a loss of investor confidence. The realistic downside could see the stock re-test its 52-week low of $20.40, representing a potential loss of approximately -47% from the current price of $38.75. This aligns with the stock's historical max drawdown of -33.34%, suggesting severe downside volatility is possible during cyclical troughs.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is burning cash, with TTM free cash flow at -$2.61B, and carries significant debt (D/E of 1.22), creating solvency concerns if the downturn is prolonged. 2) Operational Risk: Gross margins have collapsed to 5.79%, and management warns supply chain issues may take 275 days to clear, risking a delayed recovery. 3) Macro/Cyclical Risk: As a basic materials company, DOW is highly sensitive to global economic growth; a recession could further crush demand. 4) Geopolitical Risk: While de-escalating, the Middle East situation remains volatile and could re-ignite, causing renewed supply shocks.
The 12-month forecast for DOW is highly scenario-dependent. The base case (50% probability) sees the stock trading between $35 and $42 as it undergoes a slow, volatile recovery. The bull case (30% probability), fueled by a faster-than-expected margin rebound, targets a range of $42 to $48, potentially challenging new highs. The bear case (20% probability) warns of a drop to the $20-$30 range if recovery stalls and cash burn continues. The most likely outcome is the base case, predicated on the assumption that supply chain normalization proceeds gradually over the next several quarters, allowing for slow but steady fundamental improvement.
DOW is deeply undervalued based on its sales but fairly valued given its current distressed earnings. The trailing Price-to-Sales ratio of 0.416 is far below its historical level of 2.71 from a year ago and is typically very low for a chemicals company, suggesting a significant discount. However, with negative earnings, the trailing PE is meaningless, and the forward PE of 18.12 implies the market already expects a substantial profit recovery. Therefore, the stock is undervalued if a recovery occurs as expected, but it is not cheap if the current loss-making trajectory persists. The valuation implies the market is paying for a future snap-back in profitability.
DOW is a high-risk, potentially high-reward stock that may be a good buy for investors with a specific thesis and risk tolerance. It is currently a Hold for most investors. The potential upside is supported by a deep valuation discount (PS ratio of 0.416) and a major positive catalyst (Strait of Hormuz reopening). However, it is not a good buy for conservative investors due to severe near-term fundamentals, including a -$1.54B quarterly net loss and negative free cash flow. It could be a good speculative buy for those who believe in a rapid operational recovery and are willing to endure volatility, ideally on a pullback from its current level near the 52-week high.
DOW is primarily suitable for a medium- to long-term investment horizon of 12-24 months, not short-term trading. The thesis is based on a full cyclical recovery, which takes time to unfold across multiple quarters. The stock's low beta of 0.454 suggests it is less suited for short-term momentum plays, and its high recent volatility (-23% over 1 month) makes timing entries and exits difficult. The 3.6% dividend yield provides some income while waiting for the turnaround, but the payout is at risk if cash flow does not improve. Investors should be prepared to hold for at least 12-18 months to see the recovery narrative play out or be disproven.